AtaiBeckley’s MDMA-based drug for anxiety shows benefit in Phase IIa trial
EMP-01 met its primary endpoint of safety whilst also showing benefit in secondary, efficacy-based endpoints.
Therapy Area
ViiV’s four-monthly HIV drug maintains viral suppression at 12 months
FDA reversal on mRNA-1010 could transform the seasonal influenza vaccines market
Novo Nordisk-partnered drug shows 19.7% weight loss in Phase II trial
HIV patients show lower steatotic liver disease with ViiV’s Dovato vs Biktarvy
Novo Nordisk’s CagriSema bested by Lilly’s Zepbound in head-to-head trial
NeuroSense’s ALS drug improves survival in Phase IIb trial
Teva and Sanofi’s TL1A mAb shows durability in UC and CD
